Relaxin Receptor 4 Activators
Relaxin Receptor 4 (RXFP4) activators are a diverse group of chemical entities that enhance the receptor's signaling efficacy through secondary messenger cascades and kinase activation pathways. Compounds such as 8-Bromo-cAMP, IBMX, Forskolin, and Isoproterenol act by increasing intracellular cyclic AMP (cAMP) levels. The elevated cAMP activates protein kinase A (PKA), which can phosphorylate target proteins within the RXFP4 signaling cascade, consequently enhancing RXFP4 receptor activity. Similarly, compounds like Sildenafil and Vardenafil, through their inhibition of phosphodiesterase type 5, prevent the degradation of cyclic GMP (cGMP), thereby maintaining high levels of this messenger molecule. Elevated cGMP can activate cGMP-dependent protein kinases, which may then indirectly upregulate RXFP4 functional pathways. Furthermore, L-Arginine and Angiotensin II can stimulate the production of secondary messengers (NO and kinases, respectively) that can, through a series of phosphorylation events, potentially enhance RXFP4 activity.
In parallel, Insulin triggers the insulin receptor signaling pathway, which includes the activation of the PI3K/Akt pathway, potentially leading to the phosphorylation of proteins that modulate RXFP4 activity. The Peptide Hormone Atrial Natriuretic Peptide, by engaging with its receptor GC-A, leads to increased cGMP production, which in turn can foster RXFP4 signaling through cGMP-dependent kinase activation. Zaprinast, another phosphodiesterase inhibitor, raises cGMP levels, which could similarly potentiate RXFP4 signaling. YC-1, a soluble guanylyl cyclase activator, also increases cGMP levels, further contributing to the indirect activation of RXFP4 through cGMP-dependent mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromo-cAMP acts as a cAMP analog that selectively activates protein kinase A (PKA). PKA then phosphorylates specific targets that can lead to the activation of the RXFP4 receptor, thereby increasing its functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific phosphodiesterase inhibitor that prevents cAMP degradation, leading to increased cAMP levels in the cell. Elevated cAMP can enhance RXFP4 signaling by activating PKA, which in turn can phosphorylate RXFP4. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, leading to increased production of cAMP. This rise in cAMP levels activates PKA, which can phosphorylate and increase the functional activity of RXFP4. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine serves as a substrate for nitric oxide synthase, leading to the production of nitric oxide (NO). NO can stimulate guanylyl cyclase to produce cGMP, which can indirectly enhance RXFP4 activity through cGMP-dependent kinases. | ||||||
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $51.00 $100.00 $310.00 $690.00 | 3 | |
Angiotensin II engages the renin-angiotensin system and can lead to the activation of kinases that phosphorylate and enhance the activity of RXFP4 through its effects on G-protein signaling. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin can activate the insulin receptor, initiating a cascade that can lead to the activation of PI3K/Akt pathway. Akt can phosphorylate different targets, which might include components that interact with RXFP4 to enhance its activity. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, like Sildenafil, inhibits phosphodiesterase type 5, maintaining cGMP levels in cells. This inhibition can indirectly lead to enhanced RXFP4 signaling via cGMP-dependent pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a β-adrenergic agonist that can increase cAMP levels via adenylyl cyclase activation, potentially leading to enhanced PKA activity and subsequent phosphorylation that increases RXFP4 activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, leading to increased cGMP levels. Through cGMP-dependent kinases, the activation of RXFP4 could be enhanced. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
YC-1 is a soluble guanylyl cyclase activator, leading to increased levels of cGMP. Higher cGMP levels can indirectly activate RXFP4 through cGMP-dependent protein kinases. | ||||||